OpenEvidence
B2B2C ad-supported freemium: free for NPI-verified US clinicians, monetized via pharmaceutical and medical-device advertising at premium CPMs ($70-$1,000+ per Sacra, vs $5-15 for social platforms), plus emerging enterprise/EHR deployments with health systems (a non-ad enterprise tier is in development)
All primary points are reported post-money valuations from press coverage of the rounds; the mid-2026 secondary point is an indicative floor from thin, model-derived platform quotes, not a priced transaction. 12x valuation growth Feb 2025 to Jan 2026.
Where our coverage leans
Sign in to read the bull & bear take — Pro unlocks the full dossier.
Full financial intelligence for OpenEvidence
Earnings, margins & COGS, the income-statement breakdown, SWOT, moats & dependencies, the supplier–customer ecosystem graph, top signals & trends, and the valuation range.
- Income statement & margin structure
- SWOT, moats & dependency map
- Supplier–customer ecosystem graph
- Signals, trends & valuation range